Course of psychiatric symptoms and global cognition in early Parkinson disease
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received March 23, 2014
- Accepted in final form June 23, 2014
- First Published August 15, 2014.
Article Versions
- Previous version (August 15, 2014 - 13:00).
- You are viewing the most recent version of this article.
Author Disclosures
- Patricia de la Riva, MD,
- Kara Smith, MD,
- Sharon X. Xie, PhD and
- Daniel Weintraub, MD
- Patricia de la Riva, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1)Group of Young Neurologists of the Spanish Society of Neurology
NONE
NONE
NONE
NONE
NONE
NONE
- Kara Smith, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I receive an educational grant from Medtronic as a partial source of funding for my fellowship.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sharon X. Xie, PhD and
Dr. Xie served as a consultant to Roche on a clinical trial unrelated to this study.
NONE
NONE
Alzheimer's & Dementia, Associate Editor, 2013-present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Dr. Xie received funding from MJ Fox foundation and NIH grant R21-AT005230. Dr. Xie is currently funded by NIH grants P30-AG010124, P50-NS053488,P01-AG032953, P01-AG017586, R01-AT005074, R01-AG040271, and U01-NS082134.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Daniel Weintraub, MD
Commercial - Pfizer, Teva Pharmaceuticals, Avanir Pharmaceuticals, Merck & Co., Lundbeck Inc., UCB, Bristol- Myers Squib Company, Novartis, Clintrex, Theravance, Medivation Non-profit - CHDI, ADCS
NONE
NONE
Serves on Editorial Board of Movement Disorders Journal and Journal of Parkinson's Disease
NONE
NONE
NONE
NONE
NONE
Licensing fees from the University of Pennsylvania for the QUIP and QUIP-RS
NONE
Novartis Pharmaceuticals, PI, 2011-
NINDS, P50 NS053488, Investigator, 2007- NINDS, R01NS065087, Investigator, 2009-2012 NIA, RO1AG031348, Investigator, 2008- NIA, U19 AG10483-22, DSMB Chair, 2013-
NONE
Michael J. Fox Foundation for Parkinson's Research, PI, 2009-2011 Michael J. Fox Foundation for Parkinson's Research, PI, 2011- Michael J. Fox Foundation for Parkinson's Research, Investigator, 2011-
NONE
Licensing fees from the University of Pennsylvania for licensing of Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease.
NONE
NONE
NONE
Expert testimony for defense in 2012-2014 in two lawsuits related to impulse control disorders in Parkinson's disease
- From the Department of Neurology (P.d.l.R.), University Hospital Donostia, San Sebastián, Spain; Department of Biostatistics and Epidemiology (S.X.X.) and Departments of Neurology and Psychiatry (D.W.), Perelman School of Medicine at the University of Pennsylvania (K.S.), Philadelphia; and Department of Veterans Affairs (D.W.), Philadelphia VA Medical Center.
- Correspondence to Dr. de la Riva: patricia.delariva{at}gmail.com
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
Potential sex differences in nonmotor symptoms in early drug-naive Parkinson diseaseRui Liu, David M. Umbach, Shyamal D. Peddada et al.Neurology, April 29, 2015 -
Article
Baseline symptoms and basal forebrain volume predict future psychosis in early Parkinson diseaseMatthew J. Barrett, Jamie C. Blair, Scott A. Sperling et al.Neurology, April 04, 2018 -
Article
REM behavior disorder predicts motor progression and cognitive decline in Parkinson diseaseGennaro Pagano, Rosa De Micco, Tayyabah Yousaf et al.Neurology, August 08, 2018 -
Article
Selective cognitive impairment and hyposmia in p.A53T SNCA PD vs typical PDChristos Koros, Maria Stamelou, Athina Simitsi et al.Neurology, February 07, 2018